FDA 483 OBSERVATION · #721 OF 1,932 MOST-CITED

Provide space for examination

FDA cited this observation 29 times across 25 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Biologics29
BY FISCAL YEAR
FY20263
FY20251
FY20242
FY20231
FY20224
FY20211
FY20202
FY20193
FY20184
FY20173
FY20165

How FDA worded it — real examples

Failure to provide adequate space for accurate examinations of individuals to determine their eligibility as blood donors.

BioLife Plasma Services L.P. · Thornton, Colorado · Biologics · 2026-06-25

Failure to provide adequate space for private examinations of individuals to determine their eligibility as blood donors.

LifeSouth Community Blood Centers Inc · Columbus, Georgia · Biologics · 2026-02-11

Failure to provide adequate space for private examinations of individuals to determine their eligibility as blood donors.

BioLife Plasma Services LP · Fort Worth, Texas · Biologics · 2025-12-05

Failure to provide adequate space for private examinations of individuals to determine their eligibility as blood donors.

Vitalant · Denver, Colorado · Biologics · 2025-02-07

Failure to provide adequate space for private examinations of individuals to determine their eligibility as blood donors.

Hemarus LLC · Lauderhill, Florida · Biologics · 2024-04-30

Failure to provide adequate space for private and accurate examinations of individuals to determine their eligibility as blood donors.

LifeSouth Community Blood Centers, Inc · Gainesville, Georgia · Biologics · 2024-02-07

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Biologics industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →